Table V.
Cytokines in multiple immune checkpoint molecule expression on CD4+ and CD8+ T cells in malignant ascites from ovarian carcinoma.
| CD4+ T cells | CD8+ T cells | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristcs | Multiple (n=39) | Single (n=11) | None (n=4) | P-value | Multiple (n=37) | Single (n=10) | None (n=7) | P-value |
| IFNγ (pg/ml) | 378.2 | 372.8 | 430.2 | 0.85 | 369.4 | 394.3 | 420.6 | 0.48 |
| TNFα (pg/ml) | 165.0 | 174.4 | 281.2 | 0.33 | 150.2 | 202.0 | 267.7 | 0.03a |
| IL1Ra (pg/ml) | 365.0 | 380.8 | 447.3 | 0.71 | 333.5 | 463.2 | 454.3 | 0.15 |
| IL1b (pg/ml) | 9.0 | 10.1 | 13.2 | 0.65 | 7.4 | 14.2 | 13.4 | 0.11 |
| IL2 (pg/ml) | 9.4 | 8.9 | 11.0 | 0.97 | 8.9 | 9.6 | 12.1 | 0.20 |
| IL4 (pg/ml) | 7.5 | 6.7 | 8.8 | 0.81 | 6.9 | 8.4 | 9.0 | 0.04a |
| IL5 (pg/ml) | 6.4 | 6.2 | 7.6 | 0.94 | 6.2 | 7.0 | 7.3 | 0.63 |
| IL6 (pg/ml) | 5,315.4 | 4,859.1 | 6,607.5 | 0.99 | 4,411.6 | 5,742.1 | 9,246.3 | 0.02a |
| IL7 (pg/ml) | 25.3 | 26.7 | 23.9 | 0.88 | 25.9 | 25.1 | 24.1 | 0.78 |
| IL8 (pg/ml) | 905.9 | 1,410.5 | 710.7 | 0.60 | 768.5 | 1,862.4 | 907.8 | 0.23 |
| IL9 (pg/ml) | 93.7 | 97.7 | 106.4 | 0.75 | 91.6 | 101.9 | 106.1 | 0.53 |
| IL10 (pg/ml) | 178.5 | 179.2 | 187.0 | 0.96 | 153.0 | 235.3 | 231.0 | 0.12 |
| IL12 bp70 (pg/ml) | 476.2 | 500.6 | 509.5 | 0.80 | 519.8 | 327.1 | 528.3 | 0.28 |
| IL13 (pg/ml) | 31.6 | 35.5 | 36.2 | 0.46 | 33.8 | 25.7 | 37.9 | 0.56 |
| IL15 (pg/ml) | 19.4 | 31.1 | 26.0 | 0.05a | 21.4 | 24.9 | 23.8 | 0.56 |
| IL17a (pg/ml) | 90.2 | 104.0 | 124.3 | 0.42 | 88.7 | 99.4 | 124.9 | 0.36 |
| CCL2 (MCP1) (pg/ml) | 752.7 | 1179.0 | 1052.9 | 0.21 | 1020.1 | 605.1 | 468.1 | 0.12 |
| CCL3 (MIP1a) (pg/ml) | 20.2 | 18.0 | 15.7 | 0.85 | 15.6 | 37.7 | 11.9 | 0.41 |
| CCL4 (MIP1b) (pg/ml) | 825.1 | 676.4 | 787.5 | 0.78 | 746.7 | 1031.0 | 667.4 | 0.75 |
| CCL5 (Rantes) (pg/ml) | 122.4 | 221.1 | 107.1 | 0.36 | 127.9 | 255.5 | 50.9 | 0.55 |
| CXCL10 (IP10) (pg/ml) | 164,748.8 | 2,316,341.3 | 80,073.0 | 0.02a | 813,639.9 | 72,861.6 | 312,573.7 | 0.28 |
| CCL11 (Eotaxin) (pg/ml) | 349.8 | 567.7 | 297.8 | 0.25 | 426.0 | 414.8 | 188.9 | 0.40 |
| GMCSF (pg/ml) | 95.4 | 68.6 | 89.4 | 0.15 | 84.7 | 84.3 | 116.2 | 0.38 |
| bFGF (pg/ml) | 71.9 | 79.7 | 73.9 | 0.64 | 77.4 | 61.1 | 74.9 | 0.41 |
| VEGF (pg/ml) | 7,117.9 | 11,619.7 | 5,046.1 | 0.56 | 10,638.1 | 1,843.0 | 2,943.0 | 0.06 |
| PDGFbb (pg/ml) | 153.8 | 145.1 | 82.8 | 0.76 | 178.0 | 90.0 | 69.9 | 0.22 |
| GCSF (pg/ml) | 105.5 | 91.5 | 110.2 | 0.73 | 87.8 | 107.1 | 171.9 | 0.06 |
a
Statistical significance. CD, cluster of differentiation; CCL, chemokine (C-C motif) ligand; CXCL, chemokine (C-X-C motif) ligand; GMCSF, granulocyte-macrophage colony-stimulating factor; bFGF, basic fibroblast growth factor; VEGF, vascular endothelial growth factor; PDGFbb, platelet derived growth factor-BB; GCSF, granulocyte colony stimulating factor; IL, interleukin; IL1Ra, interleukin-1 receptor antagonist; TNF, tumor necrosis factor; IFN, interferon.